Logos Global Management LP
Registered adviserCIK
1792126
Location
San Francisco, CA
Portfolio Value
Mid
$2,322,922,083
Diversification
Diversified
Filing Date
Global Rank
#1,463
/ 8,818
▼ 5
Top Industry
Biotechnology
98.2%
Period ended 4 months ago
Filed Aug 14, 2026 · 2mo
26 quarters · since Mar 2020
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Holder type
Registered adviser
Form ADV roster, Oct 1, 2026
Regulatory AUM
$2,252,473,038
Main clients
Pooled investment vehicles
(100% of AUM)
Private funds
5 funds
· Venture capital funds
Focus by fund count, roster of Oct 1, 2026
$2,252,473,038 gross assets
LEI
5493000DTXD20QIYQ102
Private funds on Schedule D 7.B.(1)
As filed Apr 26, 2024; SEC's bulk Form ADV archive ends with 2024 filings.
$1,505,681,018 gross assets in 6 funds
Hedge funds
$957,789,554
(1)
Venture capital funds
$547,891,464
(5)
Form ADV history
Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Oct 2026 | $2,252,473,038 | Pooled investment vehicles (100%) |
| May 2025 to Mar 2026 | $1,435,498,601 | Pooled investment vehicles (100%) |
| Apr 2025 | $1,435,498,601 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $1,514,948,821 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $1,158,079,321 | Pooled investment vehicles (100%) |
| Apr 2023 | $1,158,079,321 | Pooled investment vehicles (100%) |
5 earlier changes not shown.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Style
Diversified active
Top 10 weight 48.3%, 29.0 effective positions, active share 96.5% against the Russell 2000 as of 2026-06-30; it meets none of the index-like, systematic-like or concentrated tests
Turnover
High turnover
111.0% over the last four quarters (100%+)
Horizon
Medium horizon
Value-weighted holding period 6.6 quarters (4 to under 12)
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 96.5%; sector active share 90.8% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
68 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
9.6%
−0.1 pts
Top 5
30.0%
−4.3 pts
Top 10
48.3%
−2.3 pts
HHI
345
Diversified−37
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.9% | $2,320,208,083 |
| Financial Services | 0.1% | $2,714,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
18 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | +1,650,000 | 2,100,000 | $78,141,000 | |
| OCUL | Ocular Therapeutix, Inc | +1,450,000 | 5,300,000 | $52,046,000 | |
| CBIO | Crescent Biopharma, Inc. | +1,417,500 | 1,900,000 | $34,200,000 | |
| MLTX | MoonLake Immunotherapeutics | +1,175,000 | 2,675,000 | $52,082,250 | |
| DYN | Dyne Therapeutics, Inc. | +1,150,000 | 2,550,000 | $56,635,500 | |
| DSGN | Design Therapeutics, Inc. | +1,050,000 | 3,000,000 | $43,410,000 | |
| ERAS | Erasca, Inc. | +1,000,000 | 12,150,000 | $222,588,000 | |
| AVTX | Avalo Therapeutics, Inc. | +850,000 | 1,150,000 | $21,252,000 | |
| JBIO | Jade Biosciences, Inc. | +725,000 | 1,125,000 | $24,997,500 | |
| MAZE | Maze Therapeutics, Inc. | +700,000 | 1,935,000 | $57,740,400 | |
| FTH | Faeth Therapeutics, Inc. | +692,020 | 722,020 | $18,050,500 | |
| AVBP | ArriVent BioPharma, Inc. | +650,000 | 1,000,000 | $34,740,000 | |
| CGON | CG Oncology, Inc. | +425,000 | 1,000,000 | $71,050,000 | |
| DNTH | Dianthus Therapeutics, Inc. | +400,000 | 800,000 | $77,984,000 | |
| ABVX | Abivax S.A. | +349,000 | 1,024,000 | $136,458,240 | |
| IRON | Disc Medicine, Inc. | +315,000 | 875,000 | $63,997,500 | |
| MANE | Veradermics, Inc | +155,000 | 180,000 | $22,129,200 | |
| NERV | Minerva Neurosciences, Inc. | +73,777 | 3,288,777 | $18,252,712 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
19 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | −1,300,000 | 700,000 | $131,096,000 | |
| IMCR | Immunocore Holdings plc | −900,000 | 600,000 | $19,050,000 | |
| RCUS | Arcus Biosciences, Inc. | −550,000 | 650,000 | $20,039,500 | |
| TRVI | Trevi Therapeutics, Inc. | −520,000 | 1,880,000 | $35,062,000 | |
| ACAD | Acadia Pharmaceuticals Inc | −500,000 | 250,000 | $6,325,000 | |
| IDYA | IDEAYA Biosciences, Inc. | −450,000 | 3,000,000 | $111,810,000 | |
| IMVT | Immunovant, Inc. | −410,000 | 665,000 | $25,622,450 | |
| RLAY | Relay Therapeutics, Inc. | −400,000 | 350,000 | $6,548,500 | |
| AMLX | Amylyx Pharmaceuticals, Inc. | −350,000 | 350,000 | $6,286,000 | |
| LBRX | Lb Pharmaceuticals Inc | −330,000 | 585,000 | $18,986,175 | |
| TENX | Tenax Therapeutics, Inc. | −325,000 | 300,000 | $4,365,000 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | −325,000 | 125,000 | $13,878,750 | |
| ACRS | Aclaris Therapeutics, Inc. | −300,000 | 200,000 | $1,058,000 | |
| IMMX | Immix Biopharma, Inc. | −225,000 | 1,000,000 | $10,310,000 | |
| TNGX | Tango Therapeutics, Inc. | −150,000 | 2,850,000 | $89,091,000 | |
| VOR | Vor Biopharma Inc. | −100,000 | 650,000 | $11,966,500 | |
| ELVN | Enliven Therapeutics, Inc. | −75,000 | 465,000 | $23,598,750 | |
| PRAX | Praxis Precision Medicines, Inc. | −25,000 | 260,000 | $87,045,400 | |
| PTN | Palatin Technologies Inc | −10,000 | 130,000 | $1,402,700 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
25 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| BNTX | BioNTech SE | 1,015,000 | $94,445,750 | |
| VERA | Vera Therapeutics, Inc. | 2,200,000 | $94,402,000 | |
| BLTE | Belite Bio, Inc | 250,000 | $38,496,250 | |
| ACHV | Achieve Life Sciences, Inc. | 5,425,000 | $35,425,250 | |
| COGT | Cogent Biosciences, Inc. | 900,000 | $34,830,000 | |
| CMPS | COMPASS Pathways plc | 2,250,000 | $31,837,500 | |
| MLYS | Mineralys Therapeutics, Inc. | 1,050,000 | $28,329,000 | |
| REPL | Replimune Group, Inc. | 2,500,000 | $27,675,000 | |
| SMMT | Summit Therapeutics Inc. | 1,350,000 | $19,669,500 | |
| CRSP | CRISPR Therapeutics AG | 300,000 | $16,362,000 | |
| DBVT | DBV Technologies S.A. | 915,000 | $15,006,000 | |
| PBLS | Parabilis Medicines, Inc. | 525,000 | $14,369,250 | |
| SRRK | Scholar Rock Holding Corp | 200,000 | $11,000,000 | |
| QTTB | Q32 Bio Inc. | 800,000 | $10,192,000 | |
| ODTX | Odyssey Therapeutics, Inc. | 521,736 | $9,761,680 | |
| ANNX | Annexon, Inc. | 1,500,000 | $8,565,000 | |
| EDIT | Editas Medicine, Inc. | 2,222,000 | $7,199,280 | |
| HELP | Helus Pharma Inc. | 750,000 | $4,957,500 | |
| OKUR | OnKure Therapeutics, Inc. | 963,855 | $4,395,178 | |
| DFTX | Definium Therapeutics, Inc. | 80,000 | $3,763,200 | |
| QURE | uniQure N.V. | 30,000 | $1,381,800 | |
| JATT | JATT II Acquisition Corp. | 100,000 | $1,136,000 | |
| RACC | Research Alliance Corp III | 100,000 | $1,070,000 | |
| LGVN | Longeveron Inc. | 1,287,000 | $904,761 | |
| AMAN | Amanat Acquisition Corp. | 50,000 | $508,000 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
20 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 2,125,000 | $84,405,000 | |
| — | 1,500,000 | $79,080,000 | ||
| CYTK | Cytokinetics Inc | 875,000 | $57,671,250 | |
| UTHR | UNITED THERAPEUTICS Corp | 80,000 | $47,438,400 | |
| MDGL | Madrigal Pharmaceuticals, Inc. | 85,000 | $44,494,950 | |
| BIIB | Biogen Inc. | 200,000 | $36,666,000 | |
| TYRA | Tyra Biosciences, Inc. | 850,000 | $32,555,000 | |
| NAMS | NewAmsterdam Pharma Co N.V. | 600,000 | $19,206,000 | |
| MIRM | Mirum Pharmaceuticals, Inc. | 200,000 | $18,476,000 | |
| PCVX | Vaxcyte, Inc. | 300,000 | $17,433,000 | |
| CMPX | Compass Therapeutics, Inc. | 3,150,000 | $16,663,500 | |
| JANX | Janux Therapeutics, Inc. | 1,000,000 | $13,900,000 | |
| ALKS | Alkermes plc. | 350,000 | $12,376,000 | |
| ORIC | Oric Pharmaceuticals, Inc. | 950,000 | $12,036,500 | |
| — | 250,000 | $8,370,000 | ||
| CRVS | Corvus Pharmaceuticals, Inc. | 450,000 | $6,583,500 | |
| MGTX | MeiraGTx Holdings plc | 700,000 | $6,062,000 | |
| VSTM | Verastem, Inc. | 1,000,000 | $5,300,000 | |
| IBIO | iBio, Inc. | 1,300,000 | $2,470,000 | |
| PHVS | Pharvaris N.V. | 65,000 | $1,836,250 | |
| No positions match the current search. | ||||
68 tracked positions ·
$2,322,922,083 total
· filing declares
68 positions · $2,322,922,487
· as of Jun 30, 2026
Showing 1–50
of 68 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ERAS |
Erasca, Inc.
Healthcare
|
Added | 12,150,000 | $222,588,000 | 9.58% | |
| ABVX |
Abivax S.A.
Healthcare
|
Added | 1,024,000 | $136,458,240 | 5.87% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Reduced | 700,000 | $131,096,000 | 5.64% | |
| IDYA |
IDEAYA Biosciences, Inc.
Healthcare
|
Reduced | 3,000,000 | $111,810,000 | 4.81% | |
| BNTX |
BioNTech SE
Healthcare
|
NEW | 1,015,000 | $94,445,750 | 4.07% | |
| VERA |
Vera Therapeutics, Inc.
Healthcare
|
NEW | 2,200,000 | $94,402,000 | 4.06% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Reduced | 2,850,000 | $89,091,000 | 3.84% | |
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
Reduced | 260,000 | $87,045,400 | 3.75% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 2,100,000 | $78,141,000 | 3.36% | |
| DNTH |
Dianthus Therapeutics, Inc.
Healthcare
|
Added | 800,000 | $77,984,000 | 3.36% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
Added | 1,000,000 | $71,050,000 | 3.06% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Added | 875,000 | $63,997,500 | 2.76% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Added | 1,935,000 | $57,740,400 | 2.49% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Added | 2,550,000 | $56,635,500 | 2.44% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
Added | 2,675,000 | $52,082,250 | 2.24% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Added | 5,300,000 | $52,046,000 | 2.24% | |
| DSGN |
Design Therapeutics, Inc.
Healthcare
|
Added | 3,000,000 | $43,410,000 | 1.87% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Held | 3,208,875 | $40,143,026 | 1.73% | |
| BLTE |
Belite Bio, Inc
Healthcare
|
NEW | 250,000 | $38,496,250 | 1.66% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
NEW | 5,425,000 | $35,425,250 | 1.53% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Reduced | 1,880,000 | $35,062,000 | 1.51% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
NEW | 900,000 | $34,830,000 | 1.50% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
Added | 1,000,000 | $34,740,000 | 1.50% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Added | 1,900,000 | $34,200,000 | 1.47% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
NEW | 2,250,000 | $31,837,500 | 1.37% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
NEW | 1,050,000 | $28,329,000 | 1.22% | |
| REPL |
Replimune Group, Inc.
Healthcare
|
NEW | 2,500,000 | $27,675,000 | 1.19% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Held | 450,000 | $27,162,000 | 1.17% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Held | 500,000 | $26,835,000 | 1.16% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Reduced | 665,000 | $25,622,450 | 1.10% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Added | 1,125,000 | $24,997,500 | 1.08% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 465,000 | $23,598,750 | 1.02% | |
| MANE |
Veradermics, Inc
Healthcare
|
Added | 180,000 | $22,129,200 | 0.95% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Reduced | 1,150,000 | $21,252,000 | 0.91% | |
| RCUS |
Arcus Biosciences, Inc.
Healthcare
|
Reduced | 650,000 | $20,039,500 | 0.86% | |
| SMMT |
Summit Therapeutics Inc.
Healthcare
|
NEW | 1,350,000 | $19,669,500 | 0.85% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Reduced | 600,000 | $19,050,000 | 0.82% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Reduced | 585,000 | $18,986,175 | 0.82% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Added | 3,288,777 | $18,252,712 | 0.79% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
Added | 722,020 | $18,050,500 | 0.78% | |
| CRSP |
CRISPR Therapeutics AG
Healthcare
|
NEW | 300,000 | $16,362,000 | 0.70% | |
| DBVT |
DBV Technologies S.A.
Healthcare
|
NEW | 915,000 | $15,006,000 | 0.65% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
NEW | 525,000 | $14,369,250 | 0.62% | |
| RYTM |
Rhythm Pharmaceuticals, Inc.
Healthcare
|
Reduced | 125,000 | $13,878,750 | 0.60% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Reduced | 650,000 | $11,966,500 | 0.52% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
NEW | 200,000 | $11,000,000 | 0.47% | |
| IMMX |
Immix Biopharma, Inc.
Healthcare
|
Reduced | 1,000,000 | $10,310,000 | 0.44% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
NEW | 800,000 | $10,192,000 | 0.44% | |
| ODTX |
Odyssey Therapeutics, Inc.
Healthcare
|
NEW | 521,736 | $9,761,680 | 0.42% | |
| ANNX |
Annexon, Inc.
Healthcare
|
NEW | 1,500,000 | $8,565,000 | 0.37% |
Showing the top 50 of 68 positions. Create a free account to see every position, past quarters, search, filters and CSV export.
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.